LEADER 02172oam  2200325z- 450 
001 9910555194803321
005 20210108010103.0
010   $a1-119-07030-9
010   $a1-119-07029-5
010   $a1-119-07015-5
035   $a(CKB)4330000000008301
035   $a(MiAaPQ)EBC5452560
035   $a(EXLCZ)994330000000008301
100   $a20180812cuuuuuuuu  -u-            -
101 0 $aeng
200 00$aOligonucleotide-based drugs and therapeutics $epreclinical and clinical considerations for development /$fedited by Nicolay Ferrari, Rosanne Seguin
210   $cJohn Wiley & Sons, Inc
311   $a1-118-53733-5 
327   $aMechanisms of oligonucleotide actions -- The medicinal chemistry of antisense oligonucleotides -- Cellular pharmacology of antisense oligonucleotides -- Pharmacokinetics and pharmacodynamics of antisense oligonucleotides -- Tissue distribution, metabolism and clearance -- Hybridization-independent effects : principles and specific considerations for oligonucleotide drugs -- Hybridization-dependent effects : the prediction, evaluation and consequences of unintended target hybridization -- Class-related proinflammatory effects -- Exaggerated pharmacology -- Genotoxicity tests for novel oligonucleotide-based therapeutics -- Reproductive and developmental toxicity testing strategies for oligonucleotide-based therapeutics -- Specific considerations for preclinical development of inhaled oligonucleotides -- Lessons learned in oncology programs -- Inhaled antisense for treatment of respiratory disease -- Antisense oligonucleotides for treatment of neurology diseases -- Nucleic acids as adjuvants -- Splice-switching oligonucleotides -- CMC aspects for the clinical development of spiegelmers.
606   $aOligonucleotides$xTherapeutic use
606   $aAntisense nucleic acids$xTherapeutic use
615  0$aOligonucleotides$xTherapeutic use.
615  0$aAntisense nucleic acids$xTherapeutic use.
676   $a572.8/5
702   $aFerrari$b Nicolay$f1969-
702   $aSeguin$b Rosanne
906   $aBOOK
912   $a9910555194803321
996   $aOligonucleotide-Based Drugs and Therapeutics$92815752
997   $aUNINA